Covid, Moderna: from August booster against Omicron 4 and 5

An updated Moderna recall for the Covid Omicron 4 and 5. “We are preparing to provide our bivalent booster vaccine starting in August, in view of a potential increase in Sars-CoV-2 infections due to the Omicron sub-variants in early autumn.” This was announced by Stéphane Bancel, CEO of the American company Moderna who today reported for the vaccine candidate mRna-1273.214 “powerful neutralizing antibody responses” against BA.4 and BA.5, Omicron 4 and 5. The new data will be sent to the regulatory authorities and for a peer reviewed publication. Read also Vaccine candidate mRna-1273.214 combines Omicron-specific booster candidate mRna-1273.529 with Covid vaccine Spikevax * (mRna-1273). “One month after administration, in people previously vaccinated and subjected to booster – reports Moderna in a note – a booster dose of 50 micrograms of mRNA-1273.214 elicited powerful neutralizing antibody responses in all participants” against Omicron 4 and 5 “. regardless of whether or not they had a previous “SARS-CoV-2 infection.” In detail, we read, “mRNA-1273.214 enhanced the neutralizing titers against BA.4 / BA.5 by 5.4 times above the baseline level in all” study participants, “regardless of previous infection, and by 6.3 times in the subgroup of seronegative participants “, that is, who had not had Covid.” Faced with the continuous evolution of Sars-CoV-2 – comments Stéphane Bancel, CEO of Moderna – we are very encouraged by the fact that mRNA-1273.214, the our main autuno booster candidate, exhibited high neutralizing titers against the subvariants BA.4 and BA.5, which pose an emerging threat to global public health. “